Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Grants

Publications

Rosenberg, J. E., P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P. A. Ott, et al. “Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study.” In Annals of Oncology, 27:vi271, 2016. https://doi.org/10.1093/annonc/mdw373.12.

Full Text

Beg, Muhammad S., Nilofer S. Azad, Sandip P. Patel, Jose Torrealba, Sharon Mavroukakis, Melony A. Beatson, Xue Ping Wang, Philip M. Arlen, and Michael A. Morse. “A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.” Cancer Chemother Pharmacol 78, no. 3 (September 2016): 577–84. https://doi.org/10.1007/s00280-016-3108-5.

PMID
27449137
Full Text

Quiroga, Dionisia, H Kim Lyerly, and Michael A. Morse. “Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.” Curr Treat Options Oncol 17, no. 8 (August 2016): 41. https://doi.org/10.1007/s11864-016-0414-4.

PMID
27315067
Full Text

Antonia, Scott J., José A. López-Martin, Johanna Bendell, Patrick A. Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, et al. “Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.” Lancet Oncol 17, no. 7 (July 2016): 883–95. https://doi.org/10.1016/S1470-2045(16)30098-5.

PMID
27269741
Full Text

Overman, Michael J., Scott Kopetz, Raymond S. McDermott, Joseph Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A. Morse, et al. “Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.” In Journal of Clinical Oncology, 34:3501–3501. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3501.

Full Text

Sharma, Padmanee, Petri Bono, Joseph W. Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi Narayana Pillai, Patrick Alexander Ott, et al. “Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.” In Journal of Clinical Oncology, 34:4501–4501. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.4501.

Full Text

Evans, M. K., S. J. Sauer, S. Nath, T. J. Robinson, M. A. Morse, and G. R. Devi. “X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.” Cell Death Dis 7 (January 28, 2016): e2073. https://doi.org/10.1038/cddis.2015.412.

PMID
26821068
Full Text

Roe, Matthew T., Derek D. Cyr, Debra Eckart, Phillip J. Schulte, Michael A. Morse, Kimberly L. Blackwell, Neal E. Ready, et al. “Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.” Eur Heart J 37, no. 4 (January 21, 2016): 412–22. https://doi.org/10.1093/eurheartj/ehv611.

PMID
26637834
Full Text

Pages